TargetNociceptin receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 23nMAssay Description:Binding affinity determined by the ability to compete with [125I]-Tyr14- nociceptin from binding to human opiate receptor-like 1 expressed in HEK293 ...More data for this Ligand-Target Pair
TargetNociceptin receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 32nMAssay Description:Binding affinity determined by the ability to compete with [125I]-Tyr14- nociceptin from binding to human opiate receptor-like 1 expressed in HEK293 ...More data for this Ligand-Target Pair
TargetNociceptin receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 37nMAssay Description:Binding affinity determined by the ability to compete with [125I]-Tyr14- nociceptin from binding to human opiate receptor-like 1 expressed in HEK293 ...More data for this Ligand-Target Pair
TargetNociceptin receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 83nMAssay Description:Binding affinity determined by the ability to compete with [125I]-Tyr14- nociceptin from binding to human opiate receptor-like 1 expressed in HEK293 ...More data for this Ligand-Target Pair
TargetKappa-type opioid receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 97nMAssay Description:Binding affinity against human opioid receptor kappa 1 expressed in HEK293 cells using 3H-U69,593 radioligandMore data for this Ligand-Target Pair
TargetNociceptin receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 100nMAssay Description:Binding affinity determined by the ability to compete with [125I]-Tyr14- nociceptin from binding to human opiate receptor-like 1 expressed in HEK293 ...More data for this Ligand-Target Pair
TargetKappa-type opioid receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 100nMAssay Description:Binding affinity against human opioid receptor kappa 1 expressed in HEK293 cells using 3H-U69,593 radioligandMore data for this Ligand-Target Pair
TargetNociceptin receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 100nMAssay Description:Binding affinity determined by the ability to compete with [125I]-Tyr14- nociceptin from binding to human opiate receptor-like 1 expressed in HEK293 ...More data for this Ligand-Target Pair
TargetNociceptin receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 120nMAssay Description:Binding affinity determined by the ability to compete with [125I]-Tyr14- nociceptin from binding to human opiate receptor-like 1 expressed in HEK293 ...More data for this Ligand-Target Pair
TargetNociceptin receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 120nMAssay Description:Binding affinity determined by the ability to compete with [125I]-Tyr14- nociceptin from binding to human opiate receptor-like 1 expressed in HEK293 ...More data for this Ligand-Target Pair
TargetKappa-type opioid receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 120nMAssay Description:Binding affinity against human opioid receptor kappa 1 expressed in HEK293 cells using 3H-U69,593 radioligandMore data for this Ligand-Target Pair
TargetNociceptin receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 140nMAssay Description:Binding affinity determined by the ability to compete with [125I]-Tyr14- nociceptin from binding to human opiate receptor-like 1 expressed in HEK293 ...More data for this Ligand-Target Pair
TargetNociceptin receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 150nMAssay Description:Binding affinity determined by the ability to compete with [125I]-Tyr14- nociceptin from binding to human opiate receptor-like 1 expressed in HEK293 ...More data for this Ligand-Target Pair
TargetNociceptin receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 180nMAssay Description:Binding affinity determined by the ability to compete with [125I]-Tyr14- nociceptin from binding to human opiate receptor-like 1 expressed in HEK293 ...More data for this Ligand-Target Pair
TargetKappa-type opioid receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 220nMAssay Description:Binding affinity against human opioid receptor kappa 1 expressed in HEK293 cells using 3H-U69,593 radioligandMore data for this Ligand-Target Pair
TargetNociceptin receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 250nMAssay Description:Binding affinity determined by the ability to compete with [125I]-Tyr14- nociceptin from binding to human opiate receptor-like 1 expressed in HEK293 ...More data for this Ligand-Target Pair
TargetKappa-type opioid receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 250nMAssay Description:Binding affinity against human opioid receptor kappa 1 expressed in HEK293 cells using 3H-U69,593 radioligandMore data for this Ligand-Target Pair
TargetNociceptin receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 290nMAssay Description:Binding affinity determined by the ability to compete with [125I]-Tyr14- nociceptin from binding to human opiate receptor-like 1 expressed in HEK293 ...More data for this Ligand-Target Pair
TargetDelta-type opioid receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 300nMAssay Description:Binding affinity against human opioid receptor delta 1 expressed in HEK293 cells using [3H]DDPDE radioligandMore data for this Ligand-Target Pair
TargetNociceptin receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 320nMAssay Description:Binding affinity determined by the ability to compete with [125I]-Tyr14- nociceptin from binding to human opiate receptor-like 1 expressed in HEK293 ...More data for this Ligand-Target Pair
TargetNociceptin receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 350nMAssay Description:Binding affinity determined by the ability to compete with [125I]-Tyr14- nociceptin from binding to human opiate receptor-like 1 expressed in HEK293 ...More data for this Ligand-Target Pair
TargetNociceptin receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 380nMAssay Description:Binding affinity determined by the ability to compete with [125I]-Tyr14- nociceptin from binding to human opiate receptor-like 1 expressed in HEK293 ...More data for this Ligand-Target Pair
TargetKappa-type opioid receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 430nMAssay Description:Binding affinity against human opioid receptor kappa 1 expressed in HEK293 cells using 3H-U69,593 radioligandMore data for this Ligand-Target Pair
TargetNociceptin receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 450nMAssay Description:Binding affinity determined by the ability to compete with [125I]-Tyr14- nociceptin from binding to human opiate receptor-like 1 expressed in HEK293 ...More data for this Ligand-Target Pair
TargetNociceptin receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 470nMAssay Description:Binding affinity determined by the ability to compete with [125I]-Tyr14- nociceptin from binding to human opiate receptor-like 1 expressed in HEK293 ...More data for this Ligand-Target Pair
TargetMu-type opioid receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 480nMAssay Description:Binding affinity against human opioid receptor mu 1 expressed in HEK293 cells using [3H]DAMGO radioligandMore data for this Ligand-Target Pair
TargetKappa-type opioid receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 480nMAssay Description:Binding affinity against human opioid receptor kappa 1 expressed in HEK293 cells using 3H-U69,593 radioligandMore data for this Ligand-Target Pair
TargetMu-type opioid receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 500nMAssay Description:Binding affinity against human opioid receptor mu 1 expressed in HEK293 cells using [3H]DAMGO radioligandMore data for this Ligand-Target Pair
TargetNociceptin receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 510nMAssay Description:Binding affinity determined by the ability to compete with [125I]-Tyr14- nociceptin from binding to human opiate receptor-like 1 expressed in HEK293 ...More data for this Ligand-Target Pair
TargetKappa-type opioid receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 540nMAssay Description:Binding affinity against human opioid receptor kappa 1 expressed in HEK293 cells using 3H-U69,593 radioligandMore data for this Ligand-Target Pair
TargetKappa-type opioid receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 560nMAssay Description:Binding affinity against human opioid receptor kappa 1 expressed in HEK293 cells using 3H-U69,593 radioligandMore data for this Ligand-Target Pair
TargetNociceptin receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 600nMAssay Description:Binding affinity determined by the ability to compete with [125I]-Tyr14- nociceptin from binding to human opiate receptor-like 1 expressed in HEK293 ...More data for this Ligand-Target Pair
TargetMu-type opioid receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 620nMAssay Description:Binding affinity against human opioid receptor mu 1 expressed in HEK293 cells using [3H]DAMGO radioligandMore data for this Ligand-Target Pair
TargetKappa-type opioid receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 640nMAssay Description:Binding affinity against human opioid receptor kappa 1 expressed in HEK293 cells using 3H-U69,593 radioligandMore data for this Ligand-Target Pair
TargetNociceptin receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 680nMAssay Description:Binding affinity determined by the ability to compete with [125I]-Tyr14- nociceptin from binding to human opiate receptor-like 1 expressed in HEK293 ...More data for this Ligand-Target Pair
TargetNociceptin receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 710nMAssay Description:Binding affinity determined by the ability to compete with [125I]-Tyr14- nociceptin from binding to human opiate receptor-like 1 expressed in HEK293 ...More data for this Ligand-Target Pair
TargetNociceptin receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 800nMAssay Description:Binding affinity determined by the ability to compete with [125I]-Tyr14- nociceptin from binding to human opiate receptor-like 1 expressed in HEK293 ...More data for this Ligand-Target Pair
TargetNociceptin receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 820nMAssay Description:Binding affinity determined by the ability to compete with [125I]-Tyr14- nociceptin from binding to human opiate receptor-like 1 expressed in HEK293 ...More data for this Ligand-Target Pair
TargetMu-type opioid receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 840nMAssay Description:Binding affinity against human opioid receptor mu 1 expressed in HEK293 cells using [3H]DAMGO radioligandMore data for this Ligand-Target Pair
TargetNociceptin receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 880nMAssay Description:Binding affinity determined by the ability to compete with [125I]-Tyr14- nociceptin from binding to human opiate receptor-like 1 expressed in HEK293 ...More data for this Ligand-Target Pair
TargetNociceptin receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 900nMAssay Description:Binding affinity determined by the ability to compete with [125I]-Tyr14- nociceptin from binding to human opiate receptor-like 1 expressed in HEK293 ...More data for this Ligand-Target Pair
TargetKappa-type opioid receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 930nMAssay Description:Binding affinity against human opioid receptor kappa 1 expressed in HEK293 cells using 3H-U69,593 radioligandMore data for this Ligand-Target Pair
TargetMu-type opioid receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 960nMAssay Description:Binding affinity against human opioid receptor mu 1 expressed in HEK293 cells using [3H]DAMGO radioligandMore data for this Ligand-Target Pair
TargetMu-type opioid receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 980nMAssay Description:Binding affinity against human opioid receptor mu 1 expressed in HEK293 cells using [3H]DAMGO radioligandMore data for this Ligand-Target Pair
TargetMu-type opioid receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 1.01E+3nMAssay Description:Binding affinity against human opioid receptor mu 1 expressed in HEK293 cells using [3H]DAMGO radioligandMore data for this Ligand-Target Pair
TargetNociceptin receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 1.08E+3nMAssay Description:Binding affinity determined by the ability to compete with [125I]-Tyr14- nociceptin from binding to human opiate receptor-like 1 expressed in HEK293 ...More data for this Ligand-Target Pair
TargetKappa-type opioid receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 1.10E+3nMAssay Description:Binding affinity against human opioid receptor kappa 1 expressed in HEK293 cells using 3H-U69,593 radioligandMore data for this Ligand-Target Pair
TargetMu-type opioid receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 1.11E+3nMAssay Description:Binding affinity against human opioid receptor mu 1 expressed in HEK293 cells using [3H]DAMGO radioligandMore data for this Ligand-Target Pair
TargetNociceptin receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 1.12E+3nMAssay Description:Binding affinity determined by the ability to compete with [125I]-Tyr14- nociceptin from binding to human opiate receptor-like 1 expressed in HEK293 ...More data for this Ligand-Target Pair
TargetKappa-type opioid receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 1.22E+3nMAssay Description:Binding affinity against human opioid receptor kappa 1 expressed in HEK293 cells using 3H-U69,593 radioligandMore data for this Ligand-Target Pair